Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011
Sign Up to like & getrecommendations! Published in 2018 at "Wiener klinische Wochenschrift"
DOI: 10.1007/s00508-018-1321-4
Abstract: SummaryBackgroundRheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease. On a national level in Austria, there are currently no data available on how often and which biological disease modifying antirheumatic drugs (bDMARDs) are prescribed… read more here.
Keywords: modifying antirheumatic; drug survival; disease modifying; biological disease ... See more keywords
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Sign Up to like & getrecommendations! Published in 2022 at "Dermatology and Therapy"
DOI: 10.1007/s13555-022-00713-1
Abstract: There is an increasing trend of malignancy worldwide. Disease-modifying antirheumatic drugs (DMARDs) are the cornerstones for the treatment of immune-mediated inflammatory diseases (IMIDs), but risk of malignancy is a major concern for patients receiving DMARDs.… read more here.
Keywords: conventional synthetic; antirheumatic drugs; disease modifying; oral conventional ... See more keywords
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/ard-2022-223356
Abstract: Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field. Methods An international task force was formed and solicited three systematic literature research activities… read more here.
Keywords: antirheumatic drugs; disease; rheumatoid arthritis; management ... See more keywords
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
Sign Up to like & getrecommendations! Published in 2023 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/ard-2022-223636
Abstract: Objective Assess cancer risks with Janus kinase inhibitors (JAKi) versus biological disease-modifying antirheumatic drugs (bDMARDs) in clinical practice. Methods Cohort study of patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) initiating treatment with JAKi,… read more here.
Keywords: antirheumatic drugs; biological disease; disease modifying; modifying antirheumatic ... See more keywords
In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora
Sign Up to like & getrecommendations! Published in 2021 at "RMD Open"
DOI: 10.1136/rmdopen-2021-001737
Abstract: Objectives In the past, the human microbiome has consistently been associated with rheumatoid arthritis (RA) and disease activity. Here, we investigate the antimicrobial activity of disease-modifying antirheumatic drugs (DMARDs) against typical representatives of the oral… read more here.
Keywords: oral microflora; antimicrobial activity; disease; rheumatoid arthritis ... See more keywords
Detecting Pharmacovigilance Signals Combining Electronic Medical Records With Spontaneous Reports: A Case Study of Conventional Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2018.00875
Abstract: Multiple data sources are preferred in adverse drug event (ADEs) surveillance owing to inadequacies of single source. However, analytic methods to monitor potential ADEs after prolonged drug exposure are still lacking. In this study we… read more here.
Keywords: conventional disease; modifying antirheumatic; disease modifying; rheumatoid arthritis ... See more keywords